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Abstract
Background: Latent tuberculosis infection (LTBI) is affecting one-third of the world population,
and activation of LTBI is a substantial source of new cases of tuberculosis. LTBI is caused by
tubercle bacilli in a state of non-replicating persistence (NRP), and the goal of this study was to
evaluate the activity in vitro of various antimicrobial agents against non-replicating M. tuberculosis.
Methods: To achieve a state of NRP we placed broth cultures of M. tuberculosis (three strains) in
anaerobic conditions, and in this model tested all known anti-TB drugs and some other
antimicrobial agents (a total of 32 drugs). The potential effect was evaluated by plating samples from
broth cultures for determining the number of viable bacteria (CFU/ml) during a prolonged period
of cultivation. Besides drug-free controls we used metronidazole for positive controls, the only
drug known so far to be effective against tubercle bacilli in anaerobic setting.
Results: On a background of non-replicating conditions in drug-free cultures and clear bactericidal
effect of metronidazole none of the antimicrobial agents tested produced effect similar to that of
metronidazole except capreomycin, which was as bactericidal at the same level as metronidazole.
Conclusion: The unique ability of capreomycin to be bactericidal in vitro among the anti-TB drugs
against non-replicating tubercle bacilli may justify the search for other drugs among peptide
antibiotics with similar activity. This phenomenon requires further studies on the mechanism of
action of capreomycin, and evaluation of its activity in appropriate animal models.
Background
Latent tuberculosis infection (LTBI) is defined as a clinical
condition without clinical or radiological signs of active
disease, and it is manifested only by a positive tuberculin
skin test [1]. Approximately two billion people, or one-
third of the world's population, have LTBI, and approxi-
mately 10% of them will develop active TB during their
lifetime. It is also estimated that one-third of all new cases
of active TB (about 2.5 million cases reported annually in
the world), results from activation of LTBI. The role of
LTBI is even greater in persons co-infected with HIV. Cur-
rently, 11 million people in this category are registered
throughout the world, and at least 10% of them develop
active TB every year. All these facts have placed the prob-
lem of diagnosis and effective treatment of LTBI in the
frontier of current TB research agenda.
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There is plenty of evidence that the basis for LTBI in
humans is persistence of tubercle bacilli in vivo for long
periods of time. This status is currently defined as dor-
mancy or non-replicating persistence (NRP) emphasizing
that each of these terms is only descriptive, regardless of
the mechanisms involved [2]. An important element of
this definition is that the suggested terms indicate not
only the constant number of tubercle bacilli over time
(stationary phase of growth in vitro), but actual lack of
multiplication. Besides LTBI, a part of bacterial popula-
tion in patients with active disease also persists in a non-
replicating state, and there is an obvious need for a drug
affecting this sub-population – a drug that would be con-
sidered for incorporation into treatment regimens.
The in vivo factors that may induce NRP include depletion
of nutrients, shifts in pH, accumulation of growth inhib-
iting products, and depletion of oxygen. Discovery of
effective drugs against non-replicating tubercle bacilli
requires appropriate in vitro models of dormancy. In the
past, the following in vitro models were suggested: cultiva-
tion at 8°C for 31 days [3], nutrient depletion [4], deple-
tion of oxygen in vigorously shaken broth cultures [5],
anaerobic model in submerged broth cultures [6], and
cultivation at pH 4.8–5.0 in broth for six weeks [7]. Not
all of these models fully comply with the above definition
of dormancy, and the most popular among them became
the anaerobic model by Wayne [6]. The physiological
parameters of NRP of M. tuberculosis in this model were
studied intensively [8-12], which makes the anaerobic
conditions the most attractive tool for further studies of
NRP.
The aim of this study was to analyze the activity of all
available anti-tuberculosis drugs in broth cultures in in
vitro anaerobic conditions. Only capreomycin was found
to be bactericidal in these conditions, and the activity of
this drug was at the same level as that of metronidazole.
Methods
Antimicrobial agents
Metronidazole was obtained from Searle (Skokie, IL). All
other drugs and reagents were obtained from Sigma (St.
Louis, MO). Stock solutions of rifampin were made in
methanol, ethionamide – in DMSO, and all other drugs –
in distilled water. Working solutions were prepared from
stock solution in 7H9 broth.
Test-strains
Three drug-susceptible strains of M. tuberculosis, H37Rv,
Erdmann, and Atencio, were kept in aliquots of 7H9 broth
culture frozen at -70°C. The inocula were prepared by 5–
7 days of sub-cultivation in fresh 7H9 broth tubes (4.5
ml) placed in a roller drum for better aeration. These cul-
tures were used as inocula when the turbidity became
equal to the optical McFarland standard #1, which corre-
sponded to about 108 CFU/ml.
Inoculum for hypoxia in vitro model
The so-called "anaerobic inoculum" of tubercle bacilli was
prepared according to the original description [6,13].
According to these reports, with conditions of gradually
decreased supply of oxygen, the tubercle bacilli undergo
an orderly metabolic down-shift into a state of dormancy
when the bacteria accumulate in the bottom of the
unshaken tubes (20 × 125 mm) containing 10 ml of
broth. In our experiments, a bacterial suspension (optical
density at #1 McFarland standard) was made from 10–14
day-old 7H11 agar culture. After homogenization with
glass beads, the suspension was placed into 25 × 125 mm
tubes, 4 ml in each, and an additional 6.0 ml of fresh 7H9
broth was added. After cultivation at 37°C for 19 days in
an undisturbed upright position, the caps were loosened
by 1/2 turn, and the tubes were placed into an anaerobic
jar for another nine days of cultivation. The jars contained
indicator strips and GasPackPlus envelopes filled with 10
ml of sterile water. Sediments were removed from tubes
by inserting pipettes through supernatants, and then com-
bined into one tube, approximately 8 ml from each four
tubes set.
Medium for anaerobic cultivation
Standard 7H12 broth in 12B Bactec vials (4.0 ml) was
supplemented with three aqueous filter-sterilized reagent
solutions, each added in a volume of 0.1 ml per vial. Two
of them were oxygen-reducing reagents: Sodium thiogly-
colate and L-cysteine hydrochlorate. The third was meth-
ylene blue, a color indicator of oxygen presence. The final
concentration was 0.5 mg/ml of each of these reagents in
the medium.
Hypoxia in vitro model: experiments with drugs
We used the Bactec-460 system set in an anaerobic mode
for testing activity of drugs in anaerobic conditions. After
addition of the above-described reagents, the bottom
edges of the caps of the12B vials were sealed by coating
with rubber cement, the drug solutions were added (0.1
ml per 4.0-ml vial), and the vials were run through the
Bactec machine with an anaerobic setting using Nitrogen
gas + 5% CO2. The vials were inoculated with the
described above bacterial suspension (0.1 ml per vial).
The vials were subsequently incubated at 37°C, and
checked daily for a possible change in color. Those with
blue color (disruption of anaerobic conditions) were dis-
carded. The vials were run through the anaerobic Bactec-
460 system every four days to record the cumulative
Growth Index (GI). To determine the number of viable
bacteria in these cultures, we took samples from alternate
vials, starting at day zero, and subsequently every week,Annals of Clinical Microbiology and Antimicrobials 2005, 4:6 http://www.ann-clinmicrob.com/content/4/1/6
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for plating appropriate dilutions on 7H11 agar plates. The
results were expressed in CFU/ml at each time-point.
Statistical analyses
We have determined the regression coefficients for each of
the curves of decline in bacterial counts (CFU/ml) in the
presence of all drugs, as well as in the drug-free controls.
For each coefficient we determined confidence limits for
the 0.95 probability, as well as its level of statistical signif-
icance (difference from the "no-decline") expressed in the
p value. In addition, we determined the statistical differ-
ence between the regression coefficients for each drug, on
one hand, and the same values found for drug-free con-
trols, also expressed as a p value.
Results
Model validation
We evaluated the kinetics of GI and CFU/ml in three pre-
liminary experiments (with three strains) using vials with-
out any drugs added and in the presence of
metronidazole. Cultivation in these preliminary experi-
ments continued up to 29 days, and samples for CFU/ml
determination were taken from alternate vials on days 0,
4, 8, 11, 15, 18, 22, 25, and 29. During this period of time,
production of CO2 in cultures remained at a steady low
level (with daily GIs less than 10), when cumulative four-
day readings on the Bactec-460 machine did not exceed GI
= 40. The number of CFU/ml in drug-free vials remained
relatively steady during this period, with only a small
decline within the first 18 days. The kinetics of CFU/ml in
vials containing metranidazole was different: a decline
could have been detected at day 8, but it became more evi-
dent (by one-to-two log10) at day 15. This decline in the
number of CFU/ml was more significant in the presence
of 32 µg/ml of metronidazole than at 8.0 µg/ml. This dif-
ference compared to the drug-free medium and between
the effects of two drug concentrations became greater dur-
ing the subsequent period. Nevertheless, we found these
differences within the first 15 days of cultivation quite suf-
ficient and less laborious for the subsequent 15 validation
experiments (five with each of the test-strains), in which
the number of CFU/ml was determined on days 0, 8, and
15. In addition, we incorporated two more agents along
with metronidazole (rifampin 0.5 µg/ml and isoniazid
0.5 µg/ml) into these experiments. The summary of these
experiments, presented in Table 1, demonstrated results
similar to that in the original report regarding activity of
these agents in anaerobic conditions (13): clear dose-
dependent bactericidal effect of metronidazole, very slight
effect of rifampin, and no effect of isoniazid. The results of
one of these experiments is also shown in Fig. 1.
Table 1: Antimicrobial Effect of Metronidazole (Met), Rifampin (RMP) and Isoniazid (INH)Against Three Strains of M. tuberculosis
Drug/ Conc. (µg/ml) Log10 of CFU/ml on days 0, 8 and 15
H37Rv Atencio Erdman
08 1 5 08 1 5 08 1 5
Control 6.76 6.30 6.04 7.26 7.49 7.34 7.08 6.63 6.30
Met. 32.0 6.76 5.18 4.20 7.26 5.73 5.76 7.08 4.70 4.18
Met. 8.0 6.76 5.70 5.72 7.26 6.49 6.20 7.08 5.88 5.18
RMP 0.5 6.76 6.11 5.91 7.26 6.50 6.50 7.08 5.76 5.59
INH 0.5 6.76 6.00 5.30 7.26 7.00 7.00 7.08 6.00 5.87
One of experiments confirming the validity of the anaerobic  model: kinetics of CFU/ml of M. tuberculosis on days 0, 8, and  15 in 7H12 broth in anaerobic conditions: in drug-free con- trol, in the presence of metronidazole (Met, 32 and 8 µg/ml),  rifampin (RMP, 0.5 µg/ml), and isoniazid (INH, 0.5 µg/ml) Figure 1
One of experiments confirming the validity of the anaerobic 
model: kinetics of CFU/ml of M. tuberculosis on days 0, 8, and 
15 in 7H12 broth in anaerobic conditions: in drug-free con-
trol, in the presence of metronidazole (Met, 32 and 8 µg/ml), 
rifampin (RMP, 0.5 µg/ml), and isoniazid (INH, 0.5 µg/ml).Annals of Clinical Microbiology and Antimicrobials 2005, 4:6 http://www.ann-clinmicrob.com/content/4/1/6
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Screening of other drugs
In subsequent experiments, each drug was tested in three
concentrations (µg/ml): amikacin (8, 4, 2), capreomycin
(8, 4, 2), ciprofloxacin (4, 2, 1), clarithromycin (32, 8, 2),
ethambutol (8, 4, 2), ethionamide (4, 2, 1), gatifloxacin
(2, 0.5, 0.12), isoniazid (2.5, 0.5, 0.1), levofloxacin (2, 1,
0.5), PAS (25 and 6.25), pyrazinamide at pH 6.0 (900,
300, 100), morphazinamide (300 and 100), rifabutin
(0.5, 0.25, 0.12), rifampin (0.5, 0.25, 0.12), rifapentine
(0.12, 0.06, 0.03), streptomycin (8, 4, 2), sparfloxacin (2,
1, 0.5), thiacetazone (1.2, 0.3, 0.075). Other drugs were
tested in single concentrations: amoxicillin, augmentin,
clindomycin, ceftriaxone, dapsone, doxycycline, erythro-
mycin, cefoxitin, gentamycin, imipenem, minocycline,
pristomycin, sulfamethoxazole, tetracycline, trimetho-
prim. Each experiment for testing two or three of the
above listed drugs always included a drug-free control and
metronidazole. The analyses included only those experi-
ments in which clear difference in the kinetics of CFU/ml
between drug-free controls and metronidazole have been
observed.
Other criteria for inclusion were: no appearance of blue
color in the media, and no greater than GI = 50 cumula-
tive readings at days 7–8, 14–15, and 21. These screening
experiments clearly demonstrated that none of the above
listed agents, except capreomycin (see below), could pro-
duce any antimicrobial activity in the model used, con-
trasting with clear bactericidal activity of metronidazole.
The results of some of these experiments are shown in
Table 2 and Fig. 2.
Activity of capreomycin in anaerobic cultures
A series of 29 experiments (six of which included capreo-
mycin) were conducted with assessment of the number of
CFU/ml at four time-points: days 0, 7, 14, and 21. Some
decline in the number of viable bacteria, at one log10 or
less, occurred in drug-free controls during this period.
Table 2: Kinetics of the Number of Viable Bacteria (Log10 CFU/ml). Initial CFU/ml Contents: H37Rv – 6.32, Atencio – 6.75, Erdman – 
6.52.
Drug/ Conc. (µg/ml) Log10 of CFU/ml on days 7, 14 and 21
H37Rv Atencio Erdman
71 4 2 171 4 2 171 4 2 1
Control 6.04 5.49 4.91 5.30 5.62 4.86 5.90 5.32 4.91
MET, 16 4.43 4.46 3.12 4.54 3.84 3.15 4.04 3.67 3.28
EMB, 8 5.86 5.39 4.91 6.17 5.30 4.71 5.82 5.28 4.72
SM, 8 6.06 5.12 4.67 6.07 5.20 4.31 5.75 5.16 4.46
PZA, 900* 5.96 5.23 4.45 5.96 5.08 4.16 5.59 5.17 4.50
*At pH 6.2
Table 3: Antimicrobial Effect of Capreomycin (CM) at Concentrations of 8, 4, and 2 µg/ml Initial CFU/ml Content: H37Rv – 7.28, 
Atencio – 6.31, Erdman – 6.88
Drug. Conc. Log10 of CFU/ml on days 7, 14 and 21
H37Rv Atencio Erdman
71 4 2 171 4 2 171 4 2 1
Control 6.54 5.85 5.80 6.25 6.30 4.92 6.78 5.20 5.31
MET, 16 5.29 4.71 3.28 5.37 6.54 3.82 6.08 5.00 3.88
CM, 8 5.72 4.57 3.13 5.56 5.97 3.24 5.68 4.88 3.18
CM, 4 5.85 4.83 3.79 5.60 6.13 3.36 5.65 5.02 3.93
CM, 2 6.17 4.82 3.88 5.83 6.26 5.62 4.71Annals of Clinical Microbiology and Antimicrobials 2005, 4:6 http://www.ann-clinmicrob.com/content/4/1/6
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Metronidazole used in a concentration of 16 µg/ml in
these experiments produced a more significant effect, with
a difference of 1–2 log10 or more compared with the
number of CFU/ml in drug-free controls at day 21 of cul-
tivation (Table 3). The effect of capreomycin at a concen-
tration of 8.0 µg/ml in these experiments was similar to
that of metronidazole, and clear dose-response relations
was seen for this effect (Table 3 and Fig. 3).
Statistical significance
Decline in the number of viable bacteria in drug-free con-
trols was not significant, with the exception being for the
strain Erdman in experiments presented in Table 1 and 2
(p < 0.05). Decline in the number of viable bacteria in the
presence of RMP and INH (Table 1) and EMB and SM
(Table 2) was not significant in experiments with strains
H37Rv and Atencio (p > 0.05). Decline in CFU/ml in the
presence of metranidazole 32.0 and 16.0 µg/ml was statis-
tically significant (p < 0.05) in all experiments, with best
results in experiments with the H37Rv strain, showing
most significant difference from decline in controls.
Capreomycin (Table 3) was most active against strain
H37Rv at concentrations of 8.0 and 4.0 µg/ml (p = 0.002
and p = 0.004, correspondingly) with definitive difference
from the curve of decline in the control (p = 0.003 and p
= 0.009, correspondingly).
Discussion
We examined the antimicrobial activity of all anti-TB
drugs and of other antimicrobial agents against M. tuber-
culosis in anaerobic conditions. For this purpose, we used
an anaerobic in vitro model based on the same principles
suggested by Wayne for submerged broth culture cultiva-
tion (6,13). Preparation of the "anaerobic inoculum" of
M. tuberculosis was identical to the procedure described in
these reports. On the other hand, to evaluate the activity
of various drugs, we used a different technology (the
Bactec-460 system) for subsequent cultivation in anaero-
bic conditions. One of the advantages of this system is
that it is less laborious for testing a large number of drugs
than the original technique. Running the culture vials
through the Bactec-460 anaerobic system with a nitrogen
gas flow effectively provided anaerobic conditions,
enforced by oxygen-reducing agents and controlled by the
color indicator present in each vial. In the past, it was
established that daily release of CO2, which was automat-
ically recorded in this system as radiometric Growth Index
(daily GI), correlates well with the increase in the number
of viable bacteria. Therefore, detection of any significant
amount of CO2 released in cultures in any of the vials pro-
vided an instant indication of possible growth, and such
vials could have been immediately removed from the
experiment. The validity of this system was confirmed in
a series of experiments to test the activity of metronida-
zole, rifampin, and isoniazid. Results obtained in these
Kinetics of CFU/ml of M. tuberculosis in anaerobic conditions  on days 0, 7, 14, and 21 in one of experiments with conven- tional anti-TB drugs compared to that of the drug-free con- trol and effect of metronidazole (Met. 16 µg/ml): ethambutol  (EMB, 8 µg/ml), streptomycin (SM, 8 µg/ml), and pyrazina- mide (PZA, 900 µg/ml, at pH 6.0) Figure 2
Kinetics of CFU/ml of M. tuberculosis in anaerobic conditions 
on days 0, 7, 14, and 21 in one of experiments with conven-
tional anti-TB drugs compared to that of the drug-free con-
trol and effect of metronidazole (Met. 16 µg/ml): ethambutol 
(EMB, 8 µg/ml), streptomycin (SM, 8 µg/ml), and pyrazina-
mide (PZA, 900 µg/ml, at pH 6.0).
Effect of capreomycin (CM, at 8, 4, and 2 µg/ml) in one of  experiments against M. tuberculosis (H37Rv) in anaerobic  conditions compared to that of metronidazole (Met, 16 µg/ ml) Figure 3
Effect of capreomycin (CM, at 8, 4, and 2 µg/ml) in one of 
experiments against M. tuberculosis (H37Rv) in anaerobic 
conditions compared to that of metronidazole (Met, 16 µg/
ml)Annals of Clinical Microbiology and Antimicrobials 2005, 4:6 http://www.ann-clinmicrob.com/content/4/1/6
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experiments were identical to those reported by Wayne
and Sramek [13].
Among all drugs listed in the Methods section, only capre-
omycin exhibited a clear bactericidal effect similar to that
of metronidazole against non-replicating M. tuberculosis in
anaerobic conditions, and this finding was confirmed in
six experiments with three M. tuberculosis strains.
We previously reported that the MICs of capreomycin in
aerobic conditions against actively multiplying M.
tuberculosis were within the range of 1.25–2.5 µg/ml in
either liquid or solid (7H11 agar) medium, and the MBC/
MIC ratio was equal to 2, similar to that of streptomycin,
amikacin, and kanamycin [14,15]. New findings that
capreomycin can be active against non-replicating M.
tuberculosis  require further investigation, particularly in
appropriate animal models. The unusual phenomenon of
such activity also requires further studies in regard to the
mode of action of this drug in anaerobic conditions. It is
well known that M. tuberculosis in NRP state represent a
problem of LTBI, but also can be a part of the bacterial
population in new patients with active tuberculosis [16].
Therefore, it is quite possible that capreomycin may not
only be effective in patients with LTBI, but also may play
an important role as an element of an initial treatment
regimen in new patients with active tuberculosis. Either of
these possibilities should be investigated in various
animal models and subsequently considered for confir-
mation in clinical trials. Setting up and conducting a
large-scale trial with LTBI patients would require a sub-
stantial period of observation and can be quite expensive.
Therefore, before addressing the issue of treatment of LTBI
patients, another option that can be considered is evalua-
tion of the potential effect of capreomycin (in a combina-
tion with other drugs) for newly diagnosed patients. This
can be achieved in pilot clinical trials using various surro-
gate markers to determine bactericidal and sterilizing
activity of drugs or drug combination [17-19]. It is prema-
ture to define the exact avenues of clinical studies until the
needed information on the effect of capreomycin in
appropriate animal models becomes available.
Conclusion
Among the known anti-TB drugs and other tested agents,
only capreomycin exhibited a bactericidal effect against
non-replicating M. tuberculosis in anaerobic conditions in
vitro. Further studies are needed to investigate the mode of
action of this drug in such a setting, as well as the efficacy
in appropriate animal models, and, perhaps, in pilot clin-
ical trials. Testing in an anaerobic dormancy model of
some other polypeptides may lead to the discovery of
other drugs effective against non-replicating M.
tuberculosis.
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